Chiesi Group to Acquire KalVista Pharmaceuticals for $1.9 Billion
Apr 29, 2026, 7:31 AM EDT4 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The acquisition premium suggests a strong positive outlook for KALV's valuation, reminiscent of robust M&A impacts in biotech.
AI summary
What happened, with direct paths to the underlying reporting
Chiesi Group has announced its acquisition of KalVista Pharmaceuticals for $1.9 billion in cash, equating to $14.75 per share. This deal, expected to close in Q1 2024, positions Chiesi to significantly enhance its product offerings in the pharmaceutical sector.
Chiesi Group to acquire KalVista for $1.9 billion cash.
KalVista shareholders to receive $14.75 per share.
Deal valued at a significant premium to KalVista's market price.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
KALV's Ekterly shows strong commercial momentum and prescriber growth. Preliminary Q4 revenue reached $35 million, with $49 million for FY 2025. Prescription refills are now the m…
KALV to report Q1 earnings on Sept. 11 with expected losses. Projected revenue for Q1 is $2.09 million. Company's shares recently fell 2.2% to $15.61. Analysts maintain bullish ra…
StockNews.AISignal intelligence